Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05589844

A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic and Lymphoid System Neoplasm Clinical Trial

Official title:
A Phase 1b Safety and Immunogenicity Study of Cytomegalovirus (CMV) Directed Type 1 Polarized Dendritic Cell Vaccination (αDC1) After Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancies

Clinical Trial Summary

This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic hematopoietic stem cell transplant. CMV is an opportunistic infection that can occur or reactivate after allogeneic hematopoietic stem cell transplant as a result of immunosuppression. The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules called cytokines, as well as CMV proteins. Introducing these dendritic cells to the patients immune system may activate an immune response to CMV, protecting against infection or reactivation.

Clinical Trial Description

PRIMARY OBJECTIVES: I. Determine the safety of cytomegalovirus (CMV) pp65 peptide loaded alpha-type 1 polarized dendritic cell (CMV-alphaDC1) vaccination after allogeneic hematopoietic cell transplantation (alloHCT). II. Determine the immunogenicity of CMV-alphaDC1 vaccination after alloHCT. SECONDARY OBJECTIVES: I. Evaluate the effect of CMV-alphaDC1 vaccination after alloHCT on late CMV reactivation. II. Evaluate the effect of CMV-alphaDC1 vaccination after alloHCT on non-relapse mortality (NRM). EXPLORATORY OBJECTIVES: I. Assess the effect of CMV-alphaDC1 vaccination on T cell subsets. II. Assess the effect of CMV-alphaDC1 vaccination on T cell receptor diversity. OUTLINE: On day 0, patients undergo standard of care hematopoietic stem cell infusion. Patients receive CMV-alphaDC1 vaccine intradermally on days 28, 42, 56, and 70. After completion of study treatment, patients are followed up at days 84, 100, 180, and 365. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05589844
Study type Interventional
Source Roswell Park Cancer Institute
Contact
Status Withdrawn
Phase Phase 1
Start date March 2023
Completion date November 16, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Completed NCT04938869 - Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer N/A
Active, not recruiting NCT04436835 - Psychotherapy (Accelerated Resolution Therapy) for Cancer Related Trauma and Distress N/A
Recruiting NCT05878405 - Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer Phase 3
Recruiting NCT06013423 - Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Phase 2
Recruiting NCT06063603 - Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study N/A
Active, not recruiting NCT05868486 - Analysis of Whole Body Magnetic Resonance Imaging and Liquid Biopsy for Early Detection of Cancer in Patients With a Strong Family History of Cancer Early Phase 1
Recruiting NCT05997589 - Financial Health Educational Program for Increasing Financial Literacy Among Underserved Communities in Western New York N/A
Recruiting NCT04572815 - Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant Phase 2
Not yet recruiting NCT06200116 - Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning
Not yet recruiting NCT05564468 - Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer N/A
Recruiting NCT04494945 - Identifying and Caring for Individuals With Inherited Cancer Syndrome N/A
Recruiting NCT05346692 - Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer Early Phase 1
Active, not recruiting NCT06104657 - Qualitative Techniques to Define Meaningful Within-Patient Change in Symptoms of Advanced Cancer Patients
Recruiting NCT03471260 - Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT05844306 - RefleXion PET/CT Imaging Performance in Patients With Various Malignancies N/A
Recruiting NCT04022239 - Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant Phase 1/Phase 2